Success Story: NIW Victory After RFE! A Chinese Senior Medical Manager Approved with Our Strategic Guidance

 

Client’s Testimonial:

“Thank you so much for the incredible service and support throughout my case. I really appreciate the team’s professionalism and efficiency in the whole process. I’m so grateful to work with your team.”

---

On June 16^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Medical Manager in the Field of Immunology (Approval Notice).

---

General Field: Immunology

Position at the Time of Case Filing: Senior Medical Manager

Country of Origin: China

Country of Residence at the Time of Filing: China

Approval Notice Date: June 16^th, 2025

Processing Time: 10 months, 23 days (Premium Processing Upgrade Requested)

---

Case Summary:           

We are proud to share the approval of an I-140 petition under the EB-2 National Interest Waiver (NIW) category for an immunology expert whose innovative work on precision medicine is helping transform the treatment landscape for autoimmune and inflammatory diseases. Although the client received a Request for Evidence (RFE), the case was ultimately approved, testament to the compelling merits of her research and its critical national relevance.

Holding an M.D. and possessing significant experience in both clinical and research settings, the petitioner has dedicated her career to investigating how immune pathways can be targeted to develop novel therapeutics. Her work focuses on identifying genetic variations in immune signaling and using multi-color flow cytometry to evaluate immune cell phenotypes, research that enables more personalized treatment options for rare and severe immune-related conditions. She is currently employed in the pharmaceutical industry and continues to pursue translational research that bridges immunology and precision drug development.

To establish her eligibility for the NIW category, the petition highlighted the following:

• ● 9 peer-reviewed journal articles and 1 conference abstract,

• ● A total of 131 citations as tracked by Google Scholar, demonstrating broad recognition and scholarly impact,

• ● Authorship of highly cited papers, including articles ranking in the top 10% and 20% for Clinical Medicine in their publication years,

• ● Research supported by funding from the National Basic Research Program of China, the National Natural Science Foundation of China, and the Chongqing Municipal Education Commission

The petitioner’s contributions have helped illuminate critical mechanisms in diseases such as systemic lupus erythematosus, Behçet’s disease, and uveitis. Her research on immune receptors, complement components, and non-coding RNAs has influenced studies worldwide, enabling other scientists to develop more effective diagnostic tools and therapeutic strategies for immune disorders.

To further support her petition, two letters of recommendation were submitted by leading experts in the field.

“[Client’s] exemplary record, marked by pioneering research in autoimmune disease pathogenesis, sets her apart as an elite scholar in her field. Her publication portfolio, distinguished by its influence on contemporary immunological paradigms, highlights her standing as an irreplaceable authority in immunology. Her record of transformative advancements has cemented her position at the apex of immunological research.”

We congratulate this client on her successful NIW approval. Through NAILG, we are honored to support driven and accomplished professionals like her, whose work on immunological precision medicine is advancing healthcare innovation and enhancing treatment strategies for some of the most challenging diseases affecting public health.